Holders — by stockHoldings — by fund
Elmind Capital, LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0002052213
$403.8M
disclosed book value
30
positions
8.9%
largest position share
Positions, as of 2026-09-30
top 30 of 30 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | CLDXCELLDEX THERAPEUTICS INC NEW | 1.1M | $36.0M | 8.9% |
| 2 | LEGNLEGEND BIOTECH CORP | 1.6M | $31.2M | 7.7% |
| 3 | SNDXSYNDAX PHARMACEUTICALS INC | 1.6M | $30.2M | 7.5% |
| 4 | COGTCOGENT BIOSCIENCES INC | 866,742 | $27.8M | 6.9% |
| 5 | RLAYRELAY THERAPEUTICS INC | 1.5M | $26.4M | 6.5% |
| 6 | AMLXAMYLYX PHARMACEUTICALS INC | 894,760 | $26.0M | 6.4% |
| 7 | VRDNVIRIDIAN THERAPEUTICS INC | 1.2M | $25.2M | 6.2% |
| 8 | PCVXVAXCYTE INC | 372,340 | $21.2M | 5.2% |
| 9 | URGNUROGEN PHARMA LTD | 491,100 | $20.0M | 4.9% |
| 10 | TVTXTRAVERE THERAPEUTICS INC | 322,600 | $19.0M | 4.7% |
| 11 | CGEMCULLINAN THERAPEUTICS INC | 962,792 | $14.8M | 3.7% |
| 12 | PHVSPHARVARIS N V | 455,750 | $14.5M | 3.6% |
| 13 | VERAVERA THERAPEUTICS INC | 436,518 | $14.1M | 3.5% |
| 14 | CTMXCYTOMX THERAPEUTICS INC. | 4.5M | $12.4M | 3.1% |
| 15 | BEAMBEAM THERAPEUTICS INC | 476,338 | $11.6M | 2.9% |
| 16 | NRIXNURIX THERAPEUTICS INC | 460,000 | $10.9M | 2.7% |
| 17 | SMMTSUMMIT THERAPEUTICS INC | 493,820 | $8.4M | 2.1% |
| 18 | UTHRUNITED THERAPEUTICS CORP DEL | 15,000 | $8.1M | 2% |
| 19 | IMCRIMMUNOCORE HLDGS PLC | 256,143 | $7.8M | 1.9% |
| 20 | KRYSKRYSTAL BIOTECH INC | 22,000 | $7.3M | 1.8% |
| 21 | ALMSALUMIS INC | 749,560 | $5.5M | 1.4% |
| 22 | BCRXBIOCRYST PHARMACEUTICALS INC | 520,000 | $4.3M | 1.1% |
| 23 | STROSUTRO BIOPHARMA INC | 228,265 | $3.7M | 0.9% |
| 24 | MBXMBX BIOSCIENCES INC | 61,000 | $3.6M | 0.9% |
| 25 | DBVTDBV TECHNOLOGIES S A | 265,000 | $3.1M | 0.8% |
| 26 | SUPNSUPERNUS PHARMACEUTICALS | 70,000 | $3.0M | 0.7% |
| 27 | BMRNBIOMARIN PHARMACEUTICAL INC | 47,000 | $2.8M | 0.7% |
| 28 | SEPNSEPTERNA INC | 49,444 | $1.9M | 0.5% |
| 29 | ALECALECTOR INC | 915,902 | $1.7M | 0.4% |
| 30 | DSGNDESIGN THERAPEUTICS INC | 107,900 | $1.4M | 0.3% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.